<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a prospective, randomized study we compared <z:chebi fb="0" ids="29007">ceftriaxone</z:chebi> (active ingredient of Rocephin) plus <z:chebi fb="0" ids="2637">amikacin</z:chebi>, <z:chebi fb="0" ids="3508">ceftazidime</z:chebi> plus <z:chebi fb="0" ids="2637">amikacin</z:chebi> and <z:chebi fb="0" ids="471744,51799">imipenem</z:chebi>/cilastatin in the empiric therapy of febrile granulocytopenic (less than 500/mm3) patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> or <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Of 27 evaluable episodes, 12 were treated with <z:chebi fb="0" ids="29007">ceftriaxone</z:chebi> plus <z:chebi fb="0" ids="2637">amikacin</z:chebi>, 5 with <z:chebi fb="0" ids="3508">ceftazidime</z:chebi> plus <z:chebi fb="0" ids="2637">amikacin</z:chebi> and 10 with <z:chebi fb="0" ids="471744,51799">imipenem</z:chebi>/cilastatin </plain></SENT>
<SENT sid="2" pm="."><plain>56% were culture-positive </plain></SENT>
<SENT sid="3" pm="."><plain><z:mpath ids='MPATH_681'>Septicemia</z:mpath> was the most frequent site of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and Escherichia coli was the most frequently isolated organism </plain></SENT>
<SENT sid="4" pm="."><plain>The efficacy of the three regimens was comparable </plain></SENT>
<SENT sid="5" pm="."><plain>One failure occurring in each treatment group was successfully treated with an alternative antibiotic regimen </plain></SENT>
<SENT sid="6" pm="."><plain>A second failure in the first treatment group did not respond to the alternative treatment either </plain></SENT>
<SENT sid="7" pm="."><plain>No major adverse effects occurred </plain></SENT>
<SENT sid="8" pm="."><plain>This study demonstrates that the three regimens are excellent in the empiric therapy of febrile granulocytopenic patients </plain></SENT>
</text></document>